Immunoembolization Outcomes for Liver-Predominant Metastatic Uveal Melanoma, 2010-2023

43 patients with liver-dominant metastatic uveal melanoma treated with immunoembolization between 2010 and 2023 at a single center. The dataset includes demographics, treatment details, and outcomes such as disease control rate, progression-free survival, and overall survival. It was created by Renee Morecroft and shared under a CC-BY-4.0 license.

Use Cases

• Compare progression-free survival outcomes based on prior systemic therapy exposure mentioned in the description.
• Analyze overall survival rates based on the reported 1-year and 2-year figures.
• Evaluate disease control rates based on the breakdown of complete response, partial response, and stable disease.
• Assess treatment duration and procedure frequency based on the median duration and mean procedures per patient.

Strengths

• Includes data for 43 patients over a 13-year period (2010-2023).
• Reports specific outcome metrics: median OS of 32.7 months, median PFS of 0.85 months, and a DCR of 27.9%.
• Contains subgroup analysis comparing outcomes for patients with and without prior systemic therapy.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center retrospective study, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Single-center retrospective analysis of clinical records.

Time Range

2010 to 2023

Freshness

Last updated 2026-04 23 04:19:56; freshness should be verified.

Geography

null